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Toulouse, and Massy, FranceObjectives The aim of this study was to compare, in a large all-comer registry, the long-term clinical
outcomesafterpercutaneous coronary intervention (PCI)withdrug-eluting stents (DES) for ostial/mid-shaft
lesions versus distal bifurcation lesions in unprotected left main coronary artery (ULMCA) stenosis.
Background Limited data are available regarding clinical outcomes following DES implantation at the
different ULMCA sites.
Methods Patients with ULMCA stenosis treated by PCI with DES were analyzed in this multinational
registry.
Results A total of 1,612 patients were included: 482 were treated for ostial/mid-shaft lesions versus
1,130 for distal bifurcation lesions. At a median follow-up period of 1,250 (interquartile range: 987 to
1,564) days, PCI for distal bifurcation lesions was associated with a higher incidence of major adverse
cardiac events (propensity-score adjusted hazard ratio [HR]: 1.48, 95% conﬁdence interval [CI]: 1.16 to
1.89; p ¼ 0.001), largely because of the higher target vessel revascularization rate observed in this
group as compared to the ostial/mid-shaft lesions group (propensity-score adjusted HR: 1.68, 95% CI:
1.19 to 2.38; p ¼ 0.003). These results were sustained following propensity-score matched analysis.
With regard to all-cause death and the composite endpoint of all-cause death and myocardial
infarction, propensity-score adjusted analysis suggested a trend toward higher rates of these in the
distal ULMCA PCI group, although this was not observed in the propensity-score matched analysis.
Conclusions This study demonstrates that PCI for ostial/mid-shaft lesions is associated with better
clinical outcomes than are distal bifurcation lesions in ULMCA, largely because there is a lower need for
repeat revascularization in ostial/mid-shaft lesions. (J Am Coll Cardiol Intv 2013;6:1242–9) ª 2013 by
the American College of Cardiology Foundation
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1243Unprotected left main coronary artery (ULMCA) disease is lesions (ostial/mid-shaft ULMCA PCI group) were
a particularly challenging lesion subset to treat; however, percu-
taneous coronary intervention (PCI) with drug-eluting stents
(DES) implantation has been shown to be a feasible and safe
approach at mid-term clinical follow-up (1–5). Previous studies
have reported favorable outcomes up to 5-year clinical follow-
up (6–13). The left main coronary artery can be divided into 3
segmentsdostial, mid-shaft, and distal bifurcations. According
to recent guidelines, PCI for an ostial or mid-shaft lesionSee page 1261Abbreviations
and Acronyms
CI = conﬁdence interval
DES = drug-eluting stent(s)
HR = hazard ratio
IABP = intra-aortic balloon
pumpof ULMCA receives a Class IIa indication (14). It is therefore
important to distinguish between ostial/mid-shaft and bifurca-
tion lesions treated in ULMCA PCI, as these can have different
clinical outcomes. Although previous studies have reported that
PCI with DES for lesions not involving the distal left main has
a better outcome than for distal left main bifurcation lesions,
the follow-upperiod in thesewasonlymid-term(15,16).Theaim
of the present study was to evaluate the long-term clinical
outcomes of PCI with DES for ostial/mid-shaft lesions, com-
paredwithPCI fordistal bifurcation lesions inULMCAinanall-
comer large, international, multicenter registry (17).LVEF = left ventricular
ejection fraction
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TLR = target lesion
revascularization
TVR = target vessel
revascularization
ULMCA = unprotected left
main coronary arteryMethods
The methods of the DELTA (Drug-Eluting Stent for Left
Main Coronary Artery Disease) registry have been published
previously (17). In brief, the registry included all-comer
patients with ULMCA disease treated with PCI or coronary
artery bypass graft between April 2002 and April 2006 in
14 centers. Of the 1,874 patients who underwent PCI
with DES, 262 patients were excluded as stenting involved
both the ostium/mid-shaft and distal bifurcation sites. Thus,
the remaining 482 patients with isolated ostial/mid-shaftFrom the *Department of Cardio-Thoracic and Vascular Diseases, San Raffaele
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lesions (distal ULMCA PCI group) (Fig. 1). Whether to
use an intra-aortic balloon pump (IABP) was left to the
discretion of the operator. When IABP was used, in most
cases, it was in the context of high-risk patients and complex
bifurcation lesions (18). Dual antiplatelet therapy (i.e.,
aspirin 100 mg daily and clopidogrel 75 mg daily or ticlo-
pidine 250 mg twice daily) was administered for at least 12
months. In the Korean center, cilostazol was also prescribed.
Angiographic follow-up was scheduled according to hospital
practice or if a noninvasive evaluation or clinical presentation
suggested ischemia.
Deﬁnitions. The deﬁnitions of the DELTA registry have
been also published previously (17). Brieﬂy, in this study, the
following events were analyzed: cardiac and all-cause death;
myocardial infarction (MI);
target lesion revascularization
(TLR); and target vessel revas-
cularization (TVR). Major
adverse cardiac events (MACE)
were deﬁned as the composite
endpoint of all-cause death, MI,
and TVR. The occurrence of
stent thrombosis was deﬁned on
the basis of the Academic
Research Consortium deﬁnitions
(19). In this subanalysis, non–Q-
wave periprocedural MI was also
included in MACE as well as all
Q-wave MI that occurred during
hospital stay and follow-up and
all spontaneous MI occurring
after hospital discharge.
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1244all-cause death, cardiac death, the composite of all-cause death
and MI, MACE, TVR, and TLR at long-term follow-up.
Statistical analysis. Data are presented as percentages and
mean  SD. In general, differences in proportions were
tested with chi-square test or Fisher exact test, and differ-
ences in continuous variables were tested with a Student
t test. Cumulative event curves were generated with the
Kaplan-Meier method and compared by the log-rank test.
A propensity-score analysis was performed to minimize
any selection bias due to the differences in clinical charac-
teristics between the 2 groups. Brieﬂy, for each patient
a propensity score indicating the likelihood of a distal
ULMCA lesion was calculated by the use of a non-
parsimonious multivariable logistic regression. A propensity
score, indicating the predicted probability of receiving
a speciﬁc treatment conditional on the observed covariates,
was then calculated from the logistic equation for each
patient. Variables included in the logistic regression model to
calculate the propensity score were age, dyslipidemia, chronic
kidney disease, EuroSCORE (European System for Cardiac
Operative Risk Evaluation), left ventricular ejection fraction
(LVEF), IABP, multivessel disease, and concomitant right
coronary artery disease. The C-statistic was 0.63, and the
Hosmer-Lemeshow test p value was 0.58, conﬁrming good
discrimination and calibration of the propensity-score model,
respectively. The individual propensity score was incorpo-
rated into Cox proportional hazards regression models as
a covariate as well as ULMCA lesion subset group to calculate
the adjusted hazard ratio (HR). In addition, to reduce the
effect of treatment-selection bias and potential confounding
in this observational study, we performed rigorous adjustment
for signiﬁcant differences in the baseline characteristics of
patients with propensity-score matching using the following
algorithm: 1:1 nearest neighbor matching. Multivariable Cox
proportional-hazards regression modeling was performed to
determine the independent predictors of the MACE with
purposeful selection of covariates. Variables associated at
univariate analysis (all with a p value of <0.1) and those
judged to be of clinical importance from previous published
reports were eligible for inclusion into the multivariable
model-building process. The goodness of ﬁt of the Cox
multivariable model was assessed with the Grønnesby-Bor-
gan-May test. Results are reported as HR with associated
95% conﬁdence interval (CI) and p value. Analyses were
carried out using SPSS for Windows (version 19.0, IBM
SPSS Inc., Chicago, Illinois).
Results
A total of 1,612 patients were included (1,154 from Europe,
271 from Asia, and 187 from United States): 482 were
treated for ostial/mid-shaft lesions (ostial/mid-shaft
ULMCA PCI group); and 1,130 for distal bifurcation
lesions (distal ULMCA PCI group). No signiﬁcantdifferences were observed with regard to lesion location
(ostial/mid-shaft; 30.5% vs. 26.9%, p ¼ 0.243) and stent
diameter (3.38  0.39 mm vs. 3.39  0.22 mm, p ¼ 0.698)
between patients treated in Europe/United States and Asia.
Baseline clinical characteristics are summarized in Table 1,
whereas lesion and procedural characteristics are illustrated
in Table 2. As expected, the SYNTAX (Synergy Between
Percutaneous Coronary Intervention With Taxus and
Cardiac Surgery) score was higher in distal ULMCA (26.1
 12.3 vs. 29.7  14.3, p < 0.001). In the ostial/mid-shaft
ULMCA PCI group, a lower incidence of IABP use (3.1%
vs. 9.0%, p < 0.001) was observed. Moreover, in the ostial/
mid-shaft ULMCA PCI group, a larger (3.51  0.36 mm
vs. 3.33  0.36 mm, p < 0.001) and shorter stent (15.9 
13.5 mm vs. 24.8  18.8 mm, p < 0.001) were used. There
were no signiﬁcant differences in the type of DES used
(p ¼ 0.100) and intravascular ultrasound use (33.4% vs.
33.7%, p ¼ 0.622).
In-hospital and follow-up MACE. The median follow-up
period was 1,250 (interquartile range: 987 to 1,564) days.
In-hospital and follow-up MACE are illustrated in Table 3.
Deﬁnite stent thrombosis occurred in 13 (0.8%) patients: 3
(0.6%) in the ostial/mid-shaft ULMCA PCI group; and 10
(0.8%) in the distal ULMCA PCI group. Probable stent
thrombosis was adjudicated in 11 (0.6%) patients: 3 (0.6%)
in the ostial/mid-shaft ULMCA PCI group; and 8 (0.7%)
in the distal ULMCA PCI group.
Study endpoints. In the distal ULMCA PCI group, there
was a higher occurrence of MACE (unadjusted HR: 1.57,
95% CI: 1.28 to 1.93; p < 0.001; propensity-score adjusted
HR: 1.48, 95% CI: 1.16 to 1.89; p ¼ 0.001), mainly due
to TVR (unadjusted HR: 1.97, 95% CI: 1.44 to 2.68;
p < 0.001; propensity-score adjusted HR: 1.68, 95% CI:
1.19 to 2.38; p ¼ 0.003). TLR was also most commonly
encountered in the distal ULMCA PCI group as compared
to the ostial/mid-shaft ULMCA PCI group (unadjusted
HR: 2.29, 95% CI: 1.53 to 3.41; p < 0.001; propensity-
score adjusted HR: 2.00, 95% CI: 1.29 to 3.10; p ¼ 0.002).
There was also a trend toward higher rates in all-cause death
(unadjusted HR: 1.31, 95% CI: 0.97 to 1.77; p ¼ 0.074;
propensity-score adjusted HR: 1.45, 95% CI: 0.99 to 2.14;
p ¼ 0.057) and in the composite endpoint of all-cause death
and MI (unadjusted HR: 1.36, 95% CI: 1.05 to 1.74;
p ¼ 0.018; propensity-score adjusted HR: 1.37, 95% CI:
1.00 to 1.86; p ¼ 0.050) in the distal ULMCA PCI group.
Following subanalysis of the distal ULMCA PCI group, as
compared to the ostial/mid-shaft ULMCA PCI group,
double-stenting was associated with a higher incidence of
MACE (unadjusted HR: 1.17, 95% CI: 1.10 to 1.24;
p < 0.001) and TVR (unadjusted HR: 1.27, 95% CI: 1.17
to 1.38; p < 0.001). However, this did not explain the worse
outcomes in the overall distal ULMCA PCI group, as
compared to the ostial/mid-shaft ULMCA PCI group, as
single-stenting was also associated with higher MACE
Figure 1. Study Population Flowchart
CABG ¼ coronary artery bypass graft; DELTA ¼ Drug-Eluting Stent for Left Main Coronary Artery Disease; PCI ¼ percutaneous coronary intervention;
ULMCA ¼ unprotected left main coronary artery.
Table 1. Baseline Clinical Characteristics
Ostial/Mid-Shaft
ULMCA PCI
(n ¼ 482)
Distal
ULMCA PCI
(n ¼ 1,130) p Value
Male 352 (73.0) 851 (75.3) 0.335
Age, yrs 64.3  11.3 66.3  11.3 0.003
Family history of CAD 149 (30.9) 341 (30.2) 0.769
Hypertension 307 (63.7) 719 (63.6) 0.980
Dyslipidemia 284 (58.9) 715 (63.3) 0.099
Smokers 231 (47.9) 513 (45.4) 0.351
Diabetes 127 (26.3) 322 (28.5) 0.379
IDDM 25 (5.2) 77 (6.8)
NIDDM 102 (21.2) 245 (21.7)
Chronic kidney disease 40 (8.3) 59 (5.2) 0.018
Clinical presentation
Stable angina/silent ischemia 244 (50.6) 570 (50.4) 0.947
Unstable angina 166 (34.4) 387 (34.2) 0.941
NSTEMI 54 (11.2) 141 (12.5) 0.472
STEMI 18 (3.7) 32 (2.8) 0.339
Previous PCI 130 (27.0) 283 (25.0) 0.417
LVEF, % 53.9  12.3 53.6  11.4 0.581
EuroSCORE 4.5  3.4 5.0  3.6 0.042
Values are n (%) or mean  SD.
CAD ¼ coronary artery disease; EuroSCORE ¼ European System for Cardiac Operative Risk
Evaluation; IDDM ¼ insulin-dependent diabetes mellitus; LVEF ¼ left ventricular ejection
fraction; NIDDM ¼ noninsulin-dependent diabetes mellitus; NSTEMI ¼ non–ST-segment
elevation myocardial infarction; PCI ¼ percutaneous coronary intervention; STEMI ¼ ST-
segment elevation myocardial infarction; ULMCA ¼ unprotected left main coronary artery.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 1 2 , 2 0 1 3 Naganuma et al.
D E C E M B E R 2 0 1 3 : 1 2 4 2 – 9 Ostial/Mid-Shaft Versus Distal Lesions in ULMCA
1245(unadjusted HR: 1.39, 95% CI: 1.11 to 1.73; p¼ 0.004) and
TVR rates (unadjusted HR: 1.54, 95% CI: 1.10 to 2.17;
p ¼ 0.013). Kaplan-Meier survival curves for all-cause
death, the composite endpoint of all-cause death and MI,
MACE, and TLR are illustrated in Figure 2.
Multivariate analysis for predictors of MACE. At Cox
regression multivariable analysis, distal ULMCA PCI (HR:
1.40, 95% CI: 1.08 to 1.80; p ¼ 0.010), LVEF (HR: 0.99,
95% CI: 0.98 to 0.99; p ¼ 0.030), stent diameter (HR: 0.57,
95% CI: 0.42 to 0.77; p < 0.001), and need for IABP (HR:
2.28, 95% CI: 1.65 to 3.14; p < 0.001) were found to be
predictors of MACE (Table 4).
Propensity-score matched analysis. After propensity-score
matching was performed, 368 patients were matched in
each group. Baseline clinical and lesion characteristics of the
matched groups are shown in the Online Appendix. The
distal ULMCA PCI group again had a higher rate of
MACE (HR: 1.48, 95% CI: 1.12 to 1.95; p ¼ 0.006),
mainly due to TVR (HR: 1.82, 95% CI: 1.23 to 2.69;
p ¼ 0.003). TLR was also most commonly encountered in
the distal ULMCA PCI group as compared to the ostial/
mid-shaft ULMCA PCI group (HR: 2.32, 95% CI: 1.41 to
3.82; p ¼ 0.001). No signiﬁcant differences between the 2
groups in all-cause death (HR: 1.32, 95% CI: 0.84 to 2.08;
p ¼ 0.230) or the composite endpoint of all-cause death and
MI (HR: 1.28, 95% CI: 0.89 to 1.84; p ¼ 0.188) were
identiﬁed. Kaplan-Meier survival curves for all-cause death,
Table 2. Lesion and Procedural Characteristics
Ostial/Mid-Shaft
ULMCA PCI
(n ¼ 482)
Distal
ULMCA PCI
(n ¼ 1,130) p Value
Multivessel disease 338 (70.1) 962 (85.1) <0.001
RCA disease 164 (34.0) 431 (38.1) 0.124
SYNTAX score* 26.1  12.3 29.7  14.3 <0.001
True bifurcation 0 624 (55.2)
Pre-dilation 177 (36.7) 536 (47.4) <0.001
Post-dilation 207 (42.9) 533 (47.1) 0.119
Atherectomy 3 (0.6) 21 (1.9) 0.112
Rotablator 5 (1.0) 20 (1.8) 0.276
Cutting balloon 69 (14.3) 81 (7.3) <0.001
IABP 15 (3.1) 102 (9.0) <0.001
IVUS 161 (33.4) 381 (33.7) 0.622
DES type 0.100
SES 281 (58.3) 599 (53.0)
PES 199 (41.3) 515 (45.6)
ZES/EES 2 (0.4) 16 (1.4)
Stent diameter, mm 3.51  0.36 3.33  0.36 <0.001
Total stent length, mm 15.9  13.5 24.8  18.8 <0.001
Number of stents per lesion 1.09  0.34 1.41  0.61 <0.001
2-stent strategy 0 460 (40.7)
Stenting technique
Crush 196 (17.3)
Mini-crush 53 (4.7)
Culotte 35 (3.1)
T-stenting 115 (10.2)
V-stenting 61 (5.5)
Post-dilation 207 (42.9) 533 (47.1) 0.123
Maximum balloon diameter,
mm
3.88  0.58 3.59  0.54 <0.001
Maximum pressure, atm 16.7  3.6 15.8  4.2 0.002
Final kissing balloon inﬂation 0 677 (59.9)
Values are n (%) or mean  SD. *The availability of SYNTAX score is 78%.
DES ¼ drug-eluting stent(s); EES ¼ everolimus-eluting stent(s); IABP ¼ intra-aortic balloon
pump; IVUS ¼ intravascular ultrasound; PES ¼ paclitaxel-eluting stent(s); RCA ¼ right coronary
artery; SES ¼ sirolimus-eluting stent(s); SYNTAX ¼ Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery; ZES ¼ zotarolimus-eluting stent(s); other
abbreviations as in Table 1.
Table 3. Cumulative Incidence of In-Hospital and Follow-Up MACE
Ostial/Mid-Shaft
ULMCA PCI
(n ¼ 482)
Distal
ULMCA PCI
(n ¼ 1,130)
In-hospital events
All-cause death 12 (2.5) 21 (1.9)
Cardiac death 11 (2.3) 18 (1.6)
Noncardiac death 1 (0.2) 3 (0.3)
Myocardial infarction 18 (3.7) 61 (5.4)
Target lesion revascularization 0 0
Target vessel revascularization 5 (1.0) 7 (0.6)
MACE 29 (6.0) 82 (7.3)
Events at follow-up
All-cause death 46 (9.5) 156 (13.8)
Cardiac death 26 (5.4) 74 (6.5)
Non-cardiac death 20 (4.1) 82 (7.3)
Myocardial infarction 20 (3.9) 36 (3.2)
Target lesion revascularization 29 (6.0) 143 (12.6)
Target vessel revascularization 45 (9.3) 200 (17.7)
MACE 92 (19.1) 322 (28.5)
Values are n (%).
MACE ¼ major adverse cardiac events; other abbreviations as in Table 1.
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1246the composite endpoint of all-cause death and MI, MACE,
and TLR in the propensity-score matched groups are
illustrated in Figure 3.Discussion
The main ﬁndings of this large multicenter, multinational,
all-comer registry are:
1. ULMCA PCI for ostial/mid-shaft lesions, as
compared to distal ULMCA PCI, is associated with
better clinical outcomes at long-term follow-up,
largely because of the lower incidence of repeat re-
vascularization for ostial/mid-shaft lesions. Withregard to all-cause death and the composite endpoint
of all-cause death and MI, propensity-score adjusted
analysis suggested a trend toward higher rates of these
in the distal ULMCA PCI group, although this was
not observed in the propensity-score matched analysis.
2. Distal ULMCA PCI, stent diameter, LVEF, and
need for IABP were found to be predictors of MACE
in multivariate analysis.
To the best of our knowledge, this study reports the longest
follow-up (median follow-up >3 years) and on the largest
number of all-comer patients who underwent PCI with DES
for ostial/mid-shaft or distal UMLCA lesions (n¼ 1,612), an
area for which limited data is available (9–11). In addition, as
patients who underwent crossover bifurcation stenting in the
ostial/mid-shaft lesion group were excluded, we believe that
the clinical outcomes reported in our study reﬂect more
accurately those for each group. In the study of Palmerini
et al. (16), comprising 1,111 patients but with only 420 of
these achieving 2-year follow-up, distal ULMCA PCI was
also associated with higher revascularization rates over
a median follow-up of 545 days. In agreement with the
aforementioned study, but over a much longer follow-up, our
study also reports higher MACE rates in the distal ULMCA
PCI group, largely because of a higher need for repeat
revascularization is distal lesions. However, it is important to
note that in the propensity-score adjusted analysis, a trend
toward higher all-cause death and the composite endpoint of
all-cause death and MI was observed in the distal group,
which was not conﬁrmed in the propensity-score matched
analysis. We cannot exclude that this is not due to the smaller
Figure 2. Freedom From MACE in Ostial/Mid-Shaft ULMCA PCI Group Versus Distal ULMCA PCI Group in the Overall Population
Freedom from all-cause death (A), from the composite endpoint of all-cause death and myocardial infarction (MI) (B), from major adverse cardiac events (MACE) (C),
and from target lesion revascularization (TLR) (D) in the overall population. Patients at risk at different times are reported below each graph. Abbreviations as in
Figure 1.
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1247sample size in the propensity-score matched analysis. The
impact of ULMCA PCI site on all-cause death and the
composite endpoint of all-cause death and MI remains thus
to be fully determined. Our study also demonstrates accept-
able TLR rates for the ostial/mid-shaft ULMCA PCI group,
at only 4.5% at 3-year follow-up, despite the fact that ﬁrst-
generation DES were used and routine angiographic follow-
up was frequently performed, likely due to the study
enrollment period (2002 to 2006). This is likely a reﬂection of
the lower lesion complexity of ostial/mid-shaft ULMCA
lesions where larger and shorter stents can be used. InTable 4. Predictors of the MACE at Cox Multivariate Analysis
HR 95% CI p Value
Age, yrs 1.01 0.99–1.02 0.180
LVEF 0.99 0.98–0.99 0.030
EuroSCORE 1.02 0.99–1.05 0.273
Distal ULMCA 1.40 1.08–1.80 0.010
Elective 0.87 0.68–1.11 0.256
IABP 2.28 1.65–3.14 <0.001
Stent diameter 0.57 0.42–0.77 <0.001
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 to 3.multivariable analysis, stent diameter, LVEF, and IABP need
and distal ULMCA PCI were found to be predictors of
MACE. Regarding LVEF and need for IABP, the results are
not surprising as lower LVEF is generally considered as
a marker of poorer prognosis even in non-PCI populations,
whereas the need of IABP is suggestive of a more critical
patient state and/or more severe disease. With regard to stent
diameter, it has been previously demonstrated and widely
accepted that smaller stent size is linked with a higher risk of
restenosis and TLR, something that has been shown also to
apply in the context of ULMCA PCI (20). As to whether the
results of our study also apply to the current PCI era, in view
of the recent improvements in PCI devices and techniques,
remains to be evaluated.
Study limitations. First, the major limitation is that this is an
observational retrospective study. Therefore, a propensity-
score adjustment was performed to adjust for differences in
baseline clinical and lesion characteristics between the 2 study
groups. In addition, a propensity-score matching was also
undertaken. Second, the majority of DES used in this study
were ﬁrst-generation DES, and thus our results may not
reﬂect outcomes for ULMCA with the newer-generation
DES currently being used. Third, details regarding distal
Figure 3. Freedom From MACE in Ostial/Mid-Shaft ULMCA PCI Group Versus Distal ULMCA PCI Group in the Propensity-Score Matched Groups
Freedom from all-cause death (A), from the composite endpoint of all-cause death and MI (B), from MACE (C), and from TLR (D) in the propensity-score matched
groups. Patients at risk at different times are reported below each graph. Abbreviations as in Figure 1 and 2.
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1248ULMCA anatomy such as Medina classiﬁcation were not
available. Thus, we cannot comment on whether the worse
outcomes seen in the distal ULMCA PCI group were due to
the anatomy of bifurcation or the choice of the technique used.
Fourth, as we do not have complete data regarding the reason
for repeat revascularization (clinically vs. angiographically
driven), we cannot exclude the possibility that the oculoste-
notic reﬂex could have driven the repeat revascularization.
Finally, the low availability (78%) of SYNTAX scores in our
cohort prevented us from using this in our data analysis.Conclusions
This study demonstrates that PCI for ostial/mid-shaft
lesions, as compared to distal bifurcation lesions in
ULMCA, is associated with better clinical outcomes largely
because of the lower need for repeat revascularization in
ostial/mid-shaft lesions.
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